Education
About Us
Working with TipRanks
Follow Us
Novartis AG (GB:0QLR)
LSE:0QLR
0QLR Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF83.61 - CHF115.98
Previous CloseN/A
Volume210.36K
Average Volume (3M)2.31M
Market Cap
CHF186.21B
Enterprise ValueCHF193.96B
Total Cash (Recent Filing)$11.46B
Total Debt (Recent Filing)$31.26B
Price to Earnings (P/E)18.8
Beta0.70
Next Earnings
Apr 29, 2025EPS Estimate
1.83Last Dividend Ex-Date
Mar 11, 2025Dividend Yield3.37%
Share Statistics
EPS (TTM)5.21
Shares Outstanding2,112,421,900
10 Day Avg. Volume2,265,768
30 Day Avg. Volume2,308,542
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)N/A
Price to Sales (P/S)5.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.99
Enterprise Value/Ebitda9.36
Forecast
1Y Price Target
CHF101.00Price Target Upside0.89% Upside
Rating ConsensusHold
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentBusiness development increased in 2024, with 24 deals secured versus ‘more than 15’ in 2023.
Financial CapacityNovartis has plenty of capacity to extend its external investments further, with USD25bn of unallocated cash accumulating over the 2025-2029 period.
Litigation SettlementNovartis has settled Kisqali litigation, securing protection until at least the first quarter of 2031.
Bears Say
Impairment ChargeShortly after the deal closure of MorphoSys, the company booked a USD900m impairment charge against this acquisition.
Patent ExpiryFY 2025 guidance indicates a slowdown in the growth outlook as patent expiries begin, with more to follow later this decade.
Pipeline ChallengesThe pipeline has limited catalysts for 2025, with some delays in drug development.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
8.95%
Mutual Funds
0.01% Other Institutional Investors
81.58% Public Companies and
Individual Investors
0QLR FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest share price was CHF83.61 and its highest was CHF115.97 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF186.21B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Apr 29, 2025 which is in 27 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Jan 31, 2025. The company reported CHF1.749 earnings per share for the quarter, beating the consensus estimate of CHF1.595 by CHF0.155.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of CHF3.5 which represents an annual dividend yield of 3.37%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.83.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,112,421,900 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.749 in its last earnings report, beating expectations of CHF1.595. Following the earnings report the stock price went up 3.13%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in GB:0QLR
---
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
---
0QLR Stock 12 Month Forecast
Average Price Target
CHF101.00
▲(0.89% Upside)
Technical Analysis
Best Analysts Covering 0QLR
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+11.49%
reiterated a buy rating 13 days ago
Copying David Evans's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +11.49% per trade.
---